Literature DB >> 22733620

On Bayesian methods of exploring qualitative interactions for targeted treatment.

Wei Chen1, Debashis Ghosh, Trivellore E Raghunathan, Maxim Norkin, Daniel J Sargent, Gerold Bepler.   

Abstract

Providing personalized treatments designed to maximize benefits and minimizing harms is of tremendous current medical interest. One problem in this area is the evaluation of the interaction between the treatment and other predictor variables. Treatment effects in subgroups having the same direction but different magnitudes are called quantitative interactions, whereas those having opposite directions in subgroups are called qualitative interactions (QIs). Identifying QIs is challenging because they are rare and usually unknown among many potential biomarkers. Meanwhile, subgroup analysis reduces the power of hypothesis testing and multiple subgroup analyses inflate the type I error rate. We propose a new Bayesian approach to search for QI in a multiple regression setting with adaptive decision rules. We consider various regression models for the outcome. We illustrate this method in two examples of phase III clinical trials. The algorithm is straightforward and easy to implement using existing software packages. We provide a sample code in Appendix A.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733620      PMCID: PMC3528020          DOI: 10.1002/sim.5429

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

2.  A false-discovery-rate-based loss framework for selection of interactions.

Authors:  Wei Chen; Debashis Ghosh; Trivellore E Raghunathan; Daniel J Sargent
Journal:  Stat Med       Date:  2008-05-20       Impact factor: 2.373

3.  ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial.

Authors:  Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

4.  Bayesian subset analysis.

Authors:  D O Dixon; R Simon
Journal:  Biometrics       Date:  1991-09       Impact factor: 2.571

Review 5.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

6.  Variable Selection for Qualitative Interactions.

Authors:  L Gunter; J Zhu; S A Murphy
Journal:  Stat Methodol       Date:  2011-01-30

7.  Automated subcellular localization and quantification of protein expression in tissue microarrays.

Authors:  Robert L Camp; Gina G Chung; David L Rimm
Journal:  Nat Med       Date:  2002-10-21       Impact factor: 53.440

8.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

9.  Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.

Authors:  Craig Reynolds; Coleman Obasaju; Michael J Schell; Xueli Li; Zhong Zheng; David Boulware; John R Caton; Linda C Demarco; Mark A O'Rourke; Gail Shaw Wright; Kristi A Boehm; Lina Asmar; Jane Bromund; Guangbin Peng; Matthew J Monberg; Gerold Bepler
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

10.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  6 in total

1.  A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.

Authors:  Lu Tian; Ash A Alizadeh; Andrew J Gentles; Robert Tibshirani
Journal:  J Am Stat Assoc       Date:  2014-10       Impact factor: 5.033

2.  Some methods for heterogeneous treatment effect estimation in high dimensions.

Authors:  Scott Powers; Junyang Qian; Kenneth Jung; Alejandro Schuler; Nigam H Shah; Trevor Hastie; Robert Tibshirani
Journal:  Stat Med       Date:  2018-03-06       Impact factor: 2.373

Review 3.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Authors:  Thomas Ondra; Alex Dmitrienko; Tim Friede; Alexandra Graf; Frank Miller; Nigel Stallard; Martin Posch
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

4.  Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting.

Authors:  Jean-Eudes Dazard; Hemant Ishwaran; Rajeev Mehlotra; Aaron Weinberg; Peter Zimmerman
Journal:  Stat Appl Genet Mol Biol       Date:  2018-02-17

5.  A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.

Authors:  Wei Chen; Gerold Bepler
Journal:  J Pers Med       Date:  2013-09-01

6.  Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study.

Authors:  Eva Petkova; R Todd Ogden; Thaddeus Tarpey; Adam Ciarleglio; Bei Jiang; Zhe Su; Thomas Carmody; Philip Adams; Helena C Kraemer; Bruce D Grannemann; Maria A Oquendo; Ramin Parsey; Myrna Weissman; Patrick J McGrath; Maurizio Fava; Madhukar H Trivedi
Journal:  Contemp Clin Trials Commun       Date:  2017-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.